City Therapeutics (CTY) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of City Therapeutics (NASDAQ: CTY) in the last few weeks:

• 11/10/2026 – City Therapeutics is now covered by Stifel Nicolaus. They set a “buy” rating and a $34.00 price target on the stock.
• 11/10/2026 – City Therapeutics is now covered by The Goldman Sachs Group. They set an “early-stage biotech” rating on the stock.
• 11/10/2026 – City Therapeutics is now covered by Jefferies Financial Group. They set a “buy” rating and a $32.00 price target on the stock.
• 11/10/2026 – City Therapeutics is now covered by Oppenheimer. They set an “outperform” rating and a $46.00 price target on the stock.
• 10/24/2026 – City Therapeutics was upgraded by Wall Street Zen to “hold”.

City Therapeutics Price Performance

NASDAQ:CTY opened at $19.62 on Wednesday. City Therapeutics, Inc. has a 12 month low of $15.81 and a 12 month high of $23.88.

Insider Activity at City Therapeutics

In other news, Director Robert Nelsen bought 170,000 shares of the stock in a transaction dated Monday, October 19th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the transaction, the director owned 13,692,507 shares of the company’s stock, valued at $246,465,126. The trade was a 1.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Arch Venture Partners Xii, Llc bought 170,000 shares of the business’s stock in a transaction that occurred on Monday, October 19th. The stock was acquired at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the completion of the acquisition, the insider owned 13,692,507 shares of the company’s stock, valued at $246,465,126. This represents a 1.26% increase in their position. The SEC filing for this purchase provides additional information.

City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.